Impact of myocardial contrast echocardiography on vascular permeability: an in vivo dose response study of delivery mode, pressure amplitude and contrast dose.
暂无分享,去创建一个
Peng Li | Douglas L. Miller | Chunyan Dou | W. Armstrong | Douglas Miller | William F Armstrong | Lu-qin Cao | Chun-Yan Dou | Peng Li | L. Cao
[1] F J Ten Cate,et al. Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results. , 1990, Journal of the American College of Cardiology.
[2] B B Goldberg,et al. Ultrasound contrast agents. , 1993, Clinics in diagnostic ultrasound.
[3] D. Dalecki,et al. Thresholds for premature contractions in murine hearts exposed to pulsed ultrasound. , 1997, Ultrasound in medicine & biology.
[4] F Forsberg,et al. Ultrasound contrast agents: a review. , 1994, Ultrasound in medicine & biology.
[5] J. Gottdiener,et al. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. , 2000, The American journal of cardiology.
[6] J B Fowlkes,et al. Mechanical bioeffects from diagnostic ultrasound: AIUM consensus statements. American Institute of Ultrasound in Medicine. , 2000, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[7] J. Murgo,et al. Benefits of reducing the cardiac cycle-triggering frequency of ultrasound imaging to increase myocardial opacification with FSO69 during fundamental and second harmonic imaging. , 1997, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[8] S. Kaul,et al. Hemodynamic characteristics, myocardial kinetics and microvascular rheology of FS-069, a second-generation echocardiographic contrast agent capable of producing myocardial opacification from a venous injection. , 1996, Journal of the American College of Cardiology.
[9] J. Weiss,et al. Phase III multicenter trial comparing the efficacy of 2% dodecafluoropentane emulsion (EchoGen) and sonicated 5% human albumin (Albunex) as ultrasound contrast agents in patients with suboptimal echocardiograms. , 1998, Journal of the American College of Cardiology.
[10] S. Kaul,et al. Myocardial contrast echocardiography. , 2004, Circulation.
[11] T. Porter,et al. Myocardial cavitational activity during continuous infusion and bolus intravenous injections of perfluorocarbon-containing microbubbles. , 2001, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[12] Martin H Kroll,et al. Bioeffects of Myocardial Contrast Microbubble Destruction by Echocardiography , 2002, Echocardiography.
[13] J. Murgo,et al. Myocardial contrast echocardiography: reliable, safe, and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent. , 1996, American heart journal.
[14] S. Rajagopalan,et al. Ultrasound-mediated transfection of canine myocardium by intravenous administration of cationic microbubble-linked plasmid DNA. , 2002, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[15] Michael D. Menger,et al. Clinically Applied Microcirculation Research , 1995 .
[16] H. Movat,et al. Simple Method for Quantitation of Enhanced Vascular Permeability 1 , 1970, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[17] Francis A. Duck,et al. The Safe Use of Ultrasound in Medical Diagnosis , 2000, Z Ultraschall in der Medizin.
[18] S. Iliceto,et al. Echocardiographic contrast imaging of the human right heart: A multicenter study of the efficacy, safety, and reproducibility of intravenous SHU‐454 , 1991, Journal of clinical ultrasound : JCU.
[19] G. V. Van Hare,et al. Contrast two-dimensional echocardiography in congenital heart disease: techniques, indications and clinical utility. , 1989, Journal of the American College of Cardiology.
[20] J G Miller,et al. Contrast Echocardiography: Current and Future Applications , 2000 .
[21] D S Segar,et al. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial. , 1998, Journal of the American College of Cardiology.
[22] P. Grayburn,et al. Safety and efficacy of QW7437, a new fluorocarbon-based echocardiographic contrast agent. , 1997, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[23] G Van Camp,et al. Destruction of Contrast Microbubbles by Ultrasound: Effects on Myocardial Function, Coronary Perfusion Pressure, and Microvascular Integrity , 2001, Circulation.
[24] D. Miller,et al. Diagnostic Ultrasound Activation of Contrast Agent Gas Bodies Induces Capillary Rupture in Mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[25] R Gramiak,et al. Echocardiography of the aortic root. , 1968, Investigative radiology.
[26] T C Skalak,et al. Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. , 1998, Circulation.
[27] J. Kisslo,et al. Detection and Exclusion of Interatrial Shunts by Two-dimensional Echocardiography and Peripheral Venous Injection , 1979, Circulation.
[28] R. M. Thomas,et al. Ultrasound contrast agents nucleate inertial cavitation in vitro. , 1995, Ultrasound in medicine & biology.
[29] A. Weyman,et al. Negative Contrast Echocardiography: A New Method for Detecting Left-to-Right Shunts , 1979, Circulation.
[30] H. Becher,et al. In vitro, animal, and human characterization of OPTISON infusions for myocardial contrast echocardiography. , 1999, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[31] Ji Song,et al. Stimulation of Arteriogenesis in Skeletal Muscle by Microbubble Destruction With Ultrasound , 2002, Circulation.
[32] N. Silverman,et al. Two-dimensional echocardiography in congenital heart disease , 1982 .
[33] P A van Der Wouw,et al. Premature ventricular contractions during triggered imaging with ultrasound contrast. , 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[34] A. DeMaria,et al. Assessment of Coronary Stenosis Severity and Transmural Perfusion Gradient by Myocardial Contrast Echocardiography: Comparison of Gray-Scale B-Mode With Power Doppler Imaging , 2000, Circulation.
[35] L. Crouse,et al. Opacification and border delineation improvement in patients with suboptimal endocardial border definition on routine echocardiography: Results of a phase III trial of sonicated albumin microspheres , 1991, Clinical cardiology.
[36] William D O'Brien,et al. Arrhythmias in Rat Hearts Exposed to Pulsed Ultrasound After Intravenous Injection of a Contrast Agent , 2002, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[37] T C Skalak,et al. Direct In Vivo Visualization of Intravascular Destruction of Microbubbles by Ultrasound and Its Local Effects on Tissue. , 1998, Circulation.